You are viewing an incomplete version of our website. Please click to reload the website as full version.

CDKN1B antibody (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1))

Details for Product anti-CDKN1B Antibody No. ABIN967391, Supplier: Log in to see
Antigen
  • CDKN1B
  • CIB
  • CIBP
  • KIP1
  • PRKDCIP
  • SIP2-28
  • p27Kip1
  • AA408329
  • AI843786
  • Kip1
  • p27
  • CDKN4
  • Cdki1b
  • P27KIP1
  • MEN1B
  • MEN4
  • cdkn1bl
  • cdkn1b
  • sb:cb611
  • wu:fb63g10
  • wu:fb64g10
  • wu:fe18e03
  • FAM14D
  • ISG12
  • ISG12A
  • P27
  • 1500011J20Rik
  • 2610202L11Rik
  • Bridge-1
Alternatives
anti-Human CDKN1B antibody for Immunohistochemistry (Frozen Sections)
Reactivity
Human, Mouse (Murine)
577
199
146
21
21
16
9
7
6
5
3
2
2
2
2
1
1
Host
Mouse
495
94
35
2
2
1
Clonality (Clone)
Monoclonal ()
Conjugate
This CDKN1B antibody is un-conjugated
31
29
27
25
25
25
6
2
2
2
2
2
2
2
2
2
2
Application
BioImaging (BI), Immunoprecipitation (IP), Western Blotting (WB)
421
301
178
103
85
73
45
30
24
16
12
6
3
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Brand BD Pharmingen™
Immunogen Mouse p27 [Kip1] (full-length) Recombinant Protein
Clone G173-524
Isotype IgG1
Cross-Reactivity Human
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. This antibody has been developed and certified for the bioimaging application. However, a routine bioimaging test is not performed on every lot. Researchers are encouraged to titrate the reagent for optimal performance.
5. Triton is a trademark of the Dow Chemical Company.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name p27 Kip1 (CDKN1B Antibody Abstract)
Background Cyclins and cyclin-dependent kinases (cdks) are evolutionarily conserved proteins that are essential for cell-cycle control in eukaryotes. Cyclins (regulatory subunits) bind to cdks (catalytic subunits) to form complexes that regulate the progression of the cell cycle. These complexes are regulated by activating and inhibitory phosphorylation events, as well as by interactions with small proteins that bind to cyclins, cdks, or cyclin-cdk complexes. These include p15, p16, p18, p19, p21 and p27 [Kip1]. p27 [Kip1] has been shown to inhibit the activity of multiple cyclin-cdk complexes, including cyclin D-cdk4, cyclin E-cdk2 and cyclin A-cdk2. p27 [Kip1] is a 27 kD protein which shares N-terminal sequence homology with p21, and like p21, p27 [Kip1] contains a nuclear localization signal in its C-terminal region. IL-2 activation of T cells has been reported to lead to a decrease in p27 [Kip1] and entry into S phase. Removal of IL-2 from T cell cultures results in increased levels of p27 [Kip1] and cell quiescence.
Molecular Weight 27 kDa
Pathways Cell Division Cycle, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Application Notes Bioimaging
1. Seed the cells in appropriate culture medium at ~10,000 cells per well in an 96-well Imaging Plate and culture overnight.
2. Remove the culture medium from the wells, and fix the cells by adding 100 myl of Fixation Buffer to each well. Incubate for 10 minutes at room temperature (RT).
3. Remove the fixative from the wells, and permeabilize the cells using either 90% methanol, or Triton™ X-100: a. Add 100 myl of -20°C 90% methanol to each well and incubate for 5 minutes at RT. OR b. Add 100 myl of 0.1% Triton™ X-100 to each well and incubate for 5 minutes at RT.
4. Remove the permeabilization buffer, and wash the wells twice with 100 myl of 1× PBS.
5. Remove the PBS, and block the cells by adding 100 myl of to each well. Incubate for 30 minutes at RT.
6. Remove the blocking buffer and add 50 myl of the optimally titrated primary antibody (diluted in Stain Buffer) to each well, and incubate for 1 hour at RT.
7. Remove the primary antibody, and wash the wells three times with 100 myl of 1× PBS.
8. Remove the PBS, and add the second step reagent at its optimally titrated concentration in 50 myl to each well, and incubate in the dark for 1 hour at RT.
9. Remove the second step reagent, and wash the wells three times with 100 myl of 1× PBS.
10. Remove the PBS, and counter-stain the nuclei by adding 200 myl per well of 2 myg/ml Hoechst 33342 in 1× PBS to each well at least 15 minutes before imaging.
11. View and analyze the cells on an appropriate imaging instrument.
Comment

Related Products: ABIN967389

Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4°C.
Supplier Images
Western Blotting (WB) image for anti-CDKN1B antibody (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1)) (ABIN967391) Immunoprecipitation/Western Blot analysis of p27 [Kip1]. Lanes 1 and 2, Equal amounts...
Immunofluorescence (IF) image for anti-CDKN1B antibody (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1)) (ABIN967391) Immunofluorescent staining of HeLa (ATCC CCL-2) cells. Cells were seeded in a 96 well...
 image for anti-CDKN1B antibody (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1)) (ABIN967391) anti-Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) antibody (Image 3)
Western Blotting (WB) image for anti-CDKN1B antibody (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1)) (ABIN967391) anti-Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) antibody (Image 4)
Product cited in: Gorospe, Liu, Xu et al.: "Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2." in: Molecular and cellular biology, Vol. 16, Issue 3, pp. 762-70, 1996 (PubMed).

Sherr: "Mammalian G1 cyclins." in: Cell, Vol. 73, Issue 6, pp. 1059-65, 1993 (PubMed).

Polyak, Kato, Solomon et al.: "p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest." in: Genes & development, Vol. 8, Issue 1, pp. 9-22, 1994 (PubMed).

Toyoshima, Hunter: "p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21." in: Cell, Vol. 78, Issue 1, pp. 67-74, 1994 (PubMed).

Nourse, Firpo, Flanagan et al.: "Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin." in: Nature, Vol. 372, Issue 6506, pp. 570-3, 1995 (PubMed).

Background publications Polyak, Lee, Erdjument-Bromage et al.: "Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals." in: Cell, Vol. 78, Issue 1, pp. 59-66, 1994 (PubMed).